APTORUM GROUP LIMITED Aptorum Group Limited announces the launch of its oncology and autoimmune discovery and development platform with an initial focus on indications including, but not limited to, non-small cell lung cancer (“NSCLC”) and autoimmune diseases such as lupus, rheumatoid arthritis, inflammatory bowel diseases, etc. Under the platform, Aptorum has and will continue to conduct its screening process for novel first-in-class small molecule and PROTAC (Degrader) based drug candidates. On this basis, Aptorum is currently conducting optimisation for selected candidates as part of its small molecule library for major targets including, but not limited to EGFR, ALK, KRAS, p53 mutations.
Aptorum has identified major unmet medical needs in third and fourth generation mutations, where applicable, for NSCLC for example and will be leveraging its existing drug discovery platform to deliver novel therapeutics for such targeted patient group.
